SCHEMBL21296980

SCHEMBL21296980

CCOC(=O)c1nn[nH]c1Sc1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
POLB P06746 2/20 0.42
NPSR1 Q6W5P4 3/20 0.41
MAPT P10636 4/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 2/20 0.39
ALOX12 P18054 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 1/20 0.39
TSHR P16473 1/20 0.38
ILK Q13418 1/20 0.37
HPGDS O60760 1/20 0.37
NPC1 O15118 2/20 0.37
KMT2A Q03164 1/20 0.37
RAB9A P51151 1/20 0.37
ELANE P08246 1/20 0.37
JAK2 O60674 1/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799098 1.00 KDM4E (0.43) KDM4EPOLBNPSR1MAPTLMNA
SCHEMBL21296944 0.85 MAPT (0.56) KDM4EPOLBNPSR1MAPTLMNA
SCHEMBL29799115 0.85 MAPT (0.56) KDM4EPOLBNPSR1MAPTLMNA
SCHEMBL21296901 0.80 HAO1 (0.38) KDM4EPOLBMAPTALDH1A1
SCHEMBL29799106 0.80 HAO1 (0.38) KDM4EPOLBMAPTALDH1A1
SCHEMBL21296903 0.75 MAPT (0.44) KDM4EPOLBNPSR1MAPTELANE
SCHEMBL21296915 0.75 ALPL (0.47) KDM4ENPSR1MAPTTP53ALOX12
SCHEMBL21296967 0.74 NPC1 (0.48) KDM4EPOLBNPSR1MAPTLMNA
SCHEMBL23001880 0.74 CYP19A1 (0.43) KDM4EPOLBNPSR1MAPTALOX12
SCHEMBL29891693 0.74 CYP19A1 (0.43) KDM4EPOLBNPSR1MAPTALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX KDM4E 3780/4885POLB 1966/4885NPSR1 3194/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX KDM4E 3780/4885POLB 1966/4885NPSR1 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.